Phreesia, Inc. $PHR Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group cut its holdings in Phreesia, Inc. (NYSE:PHR) by 9.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 798,945 shares of the company’s stock after selling 82,071 shares during the quarter. Schroder Investment Management Group owned about 1.33% of Phreesia worth $18,815,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PHR. Federated Hermes Inc. purchased a new stake in shares of Phreesia during the third quarter worth about $32,000. Asset Management One Co. Ltd. purchased a new position in shares of Phreesia in the 3rd quarter valued at approximately $45,000. State of Alaska Department of Revenue purchased a new position in shares of Phreesia in the 3rd quarter valued at approximately $83,000. Tower Research Capital LLC TRC boosted its stake in Phreesia by 332.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after purchasing an additional 4,313 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Phreesia by 129.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 6,449 shares of the company’s stock worth $152,000 after purchasing an additional 3,633 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Stock Down 2.9%

Phreesia stock opened at $11.01 on Friday. The business’s 50-day moving average price is $13.81 and its 200 day moving average price is $19.37. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm has a market cap of $663.97 million, a price-to-earnings ratio of -110.12 and a beta of 0.67. Phreesia, Inc. has a 52 week low of $10.99 and a 52 week high of $32.76.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 8th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) EPS. As a group, sell-side analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Insider Transactions at Phreesia

In related news, General Counsel Allison C. Hoffman sold 6,585 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $112,010.85. Following the sale, the general counsel owned 174,762 shares in the company, valued at approximately $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the transaction, the insider directly owned 231,723 shares of the company’s stock, valued at $3,941,608.23. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 60,766 shares of company stock worth $1,013,817. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on PHR shares. Wall Street Zen lowered shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Truist Financial set a $24.00 price objective on shares of Phreesia in a research note on Thursday, January 8th. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, December 9th. JPMorgan Chase & Co. cut their target price on Phreesia from $29.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 20th. Finally, BMO Capital Markets initiated coverage on Phreesia in a research report on Thursday, November 13th. They set an “outperform” rating and a $32.00 price target for the company. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.12.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.